Nanoparticles for Traumatic Brain Injury
Our nanoparticles for traumatic brain injury (TBI) research goal is to improve treatment of TBI, which has seen little advancement over the past century although it is the leading cause of death and disability in children and adults under 45. We are developing theranostic (combined therapeutic and diagnostic) nanoparticles that can accumulate in damaged brain and reduce long-term secondary effects through histopathological and behavioral analyses in mice.
NPs for TBI z-stack confocal


Nanoparticles for Brain Cancer
We are engineering nanoparticle-based drugs to improve the therapy of pediatric brain cancers. Our goal is to enhance the effects of radiation and chemo therapies on the cancer cells so that safe doses of therapy that do not harm the healthy brain can be used to kill the tumor.

Pediatric brain cancer cells are extraordinarily good at repairing themselves from the damage caused by radiation and chemo therapies. We are developing gene therapy nanoparticles that can inhibit the cell’s ability to repair itself from this damage. These nanoparticles are tiny beads about 1/100,000th the diameter of a human hair. Their small size has allowed us to finely tune their properties at the molecular level to help them deliver treatments specifically to tumors. To the nanoparticles we attach various therapeutics such as siRNA, a small DNA-like molecule, or small molecule drugs that shut down cancer cell repair machinery. These nanoparticles comprise a magnetic contrast agent, which can be imaged using magnetic resonance imaging (MRI) enabling real-time observation of its delivery. This provides a significant advantage over current therapy where delivery cannot be monitored.

NPs for brain cancer

Nanoparticles for Aging
There are numerous diseases related to aging-based neurocognitive decline. Therapy of these diseases is significantly limited by the difficulty in delivery of therapeutics into the brain because of the presence of the blood-brain barrier; thus, a major focus is to improve delivery across this barrier. However, this results in delivery throughout the brain including regions that are normally functioning. We are taking a different approach - our goal is to achieve specific delivery only in regions of brain that are experiencing dysfunction. To do this, we are engineering nanoparticles that can specifically bind to regions of the blood-brain barrier that show endothelial cell surface markers of dysfunction. Our goal improve therapeutic outcomes by using our novel targeted approach to improve therapeutic target engagement.

CLDN1 targeting

CLDN1 confocal

Magnetic Resonance Imaging
Our lab houses a 9.4T vertical bore Varian magnet for MR imaging of tissues and mice. Please contact us if you're interested in any imaging applications.
9.4 T MRI

High resolution scans of a mouse brain
mouse brain 1 mouse brain 2

3D MR image of mouse brain
3D MR image of mouse brain

3D MR image of contrast enhanced brain injury
Contrast enhanced brain injury

Diffusion tensor imaging and tractography in TBI

DTI    Tractography